Annual Report

Overview

The report describes 2017 as a transformative year for the company, highlighting positive clinical data, completion of recruitment for the Phase II MERECA study, and capital raised for MERECA and the Nasdaq Stockholm uplisting. It records regulatory and clinical progress, including French CTA approval and positive topline data from the HCC Phase I/II study. The report also notes a 90% secured rights issue that raised approximately SEK 200 million before transaction costs.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2017
Period: 1 January 2017 – 31 December 2017
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services